Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2
Authors:
- Yu. Yu. PolyakovYPYu. Yu. Polyakov
- E. A. BaryakhEBE. A. Baryakh
- E. N. MisyurinaEME. N. Misyurina
- E. I. ZhelnovaEZE. I. Zhelnova
- M. A. MingalimovMMM. A. Mingalimov
- S. A. KardovskayaSKS. A. Kardovskaya
- M. Ya. SmolyarchukMSM. Ya. Smolyarchuk
- T. N. TolstykhTTT. N. Tolstykh
- T. S. ChudnovaTCT. S. Chudnova
- D. D. IvanovaDID. D. Ivanova
- O. L. KochnevaOKO. L. Kochneva
- D. V. LebedevDLD. V. Lebedev
Open Access
- 2 April 2024
- journal article
- research article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 101-108
Abstract
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.Keywords
This publication has 6 references indexed in Scilit:
- The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case StudyOpen Forum Infectious Diseases, 2021
- Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional studyJournal of Infection, 2021
- Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir TherapyThe Journal of Infectious Diseases, 2020
- Immune Response, Inflammation, and the Clinical Spectrum of COVID-19Frontiers in Immunology, 2020
- Prolonged SARS‐CoV‐2 RNA shedding: Not a rare phenomenonJournal of Medical Virology, 2020
- Immune privilege or privileged immunity?Mucosal Immunology, 2008